Brief Title: RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Phase Ia: Number of Participants with Dose Limiting Toxicities (DLTs)

Primary Outcome 1 - Timeframe: From Day 1 to Day 21 of Cycle 1 (21 days from date of first dose of study treatment)

Primary Outcome 2 - Measure: Phase Ib: Number of Participants with DLTs

Primary Outcome 2 - Timeframe: From Day 1 to Day 21 of Cycle 1 (21 days from date of first dose of study treatment)

Primary Outcome 3 - Measure: Phase Ia: Number of Participants with Treatment Emergent Adverse Events

Primary Outcome 3 - Timeframe: Up to approximately 5 years

Primary Outcome 4 - Measure: Phase Ib: Number of Participants with Treatment Emergent Adverse Events

Primary Outcome 4 - Timeframe: Up to approximately 5 years

CONDITION

• Locally Advanced or Metastatic Solid Tumors
• NSCLC
• HNSCC
• Melanoma
• TNBC
• Esophageal Cancer
• Gastric Cancer
• Cervical Cancer
• Colorectal Cancer
• Urothelial Carcinoma
• Clear Cell RCC
• HCC

ELIGIBILITY

Inclusion Criteria:
* Life expectancy at least 12 weeks

- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- * Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1

- * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy

- * Tumor Specimen availability
Exclusion Criteria:
* Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of RO7501275, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab

- * Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment

- * Active hepatitis B or C or tuberculosis

- * Positive test for human immunodeficiency virus (HIV) infection

- * Acute or chronic active Epstein-Barr virus (EBV) infection at screening

- * Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion

- * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases

- * Active or history of autoimmune disease

- * Prior allogeneic stem cell or organ transplantation

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: Reference Study ID Number: GO43860 https://forpatients.roche.com/

Phone: 888-662-6728 (U.S. Only)

Email: [email protected]

LOCATION